This transcript has been edited for clarity.
Hi, everyone. It's Dr Kathy Miller from Indiana University. I came across an article in JAMA Oncology this July that is both sobering and not terribly surprising. I want to make sure you have a chance to see it and think about it as well.
This study looked at a comparison between patients treated in the real world — as in, not part of a clinical trial — compared with the results reported in clinical trials with the same baseline therapy. This is work from Dr Christopher Booth and his colleagues in Ontario, and they evaluated 795 patients treated with pertuzumab-based regimens for metastatic HER2-positive therapy and 506 patients treated with trastuzumab emtansine (T-DM1), also for metastatic HER2-positive disease.
In the pertuzumab group, median overall survival was 43 months, which was significantly shorter than in the pivotal trial. In the T-DM1 group, median overall survival was 15 months, also significantly shorter.
We should not assume that this means the clinical trial results were wrong, done incorrectly, or somehow fraudulent. The real world is different. Patients tend to be a little bit older and have more previous therapy. There was less fidelity to the rigors of organ function and all of the details that go into patients who are treated in clinical trials.
COMMENTARY
Real-World Metastatic Breast Cancer Treatments Fall Far Short of Pivotal Trial Outcomes
Kathy D. Miller, MD
DisclosuresNovember 11, 2021
This transcript has been edited for clarity.
Hi, everyone. It's Dr Kathy Miller from Indiana University. I came across an article in JAMA Oncology this July that is both sobering and not terribly surprising. I want to make sure you have a chance to see it and think about it as well.
This study looked at a comparison between patients treated in the real world — as in, not part of a clinical trial — compared with the results reported in clinical trials with the same baseline therapy. This is work from Dr Christopher Booth and his colleagues in Ontario, and they evaluated 795 patients treated with pertuzumab-based regimens for metastatic HER2-positive therapy and 506 patients treated with trastuzumab emtansine (T-DM1), also for metastatic HER2-positive disease.
In the pertuzumab group, median overall survival was 43 months, which was significantly shorter than in the pivotal trial. In the T-DM1 group, median overall survival was 15 months, also significantly shorter.
We should not assume that this means the clinical trial results were wrong, done incorrectly, or somehow fraudulent. The real world is different. Patients tend to be a little bit older and have more previous therapy. There was less fidelity to the rigors of organ function and all of the details that go into patients who are treated in clinical trials.
Medscape Oncology © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kathy D. Miller. Real-World Metastatic Breast Cancer Treatments Fall Far Short of Pivotal Trial Outcomes - Medscape - Nov 11, 2021.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Kathy D. Miller, MD
Professor of Medicine, Indiana University School of Medicine; Co-director, Breast Cancer Program, Indiana University Simon Cancer Center, Indianapolis, Indiana
Disclosure: Kathy D. Miller, MD, has disclosed no relevant financial relationships.